Enzymatica AB (STU:EN9) EPS (Basic): €-0.02 (TTM As of Mar. 2026)


STU:EN9 Enzymatica AB STU:EN9
58 GF Score
Price €0.18
GF Value €0.16
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB EPS (Basic)?

Enzymatica AB STU:EN9 -2.73% 58 EPS (Basic) is €-0.02 as of Mar. 2026. GuruFocus rates STU:EN9 with a GF Score™ of 58/100 and a GF Value™ of €0.16. The stock has 2 warning signs investors should review.

Enzymatica AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02.

Enzymatica AB's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02.

Enzymatica AB's EPS without NRI for the three months ended in Mar. 2026 was €-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.02.

During the past 3 years, the average EPS without NRI Growth Rate was 19.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -12.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Enzymatica AB's highest 3-Year average EPS without NRI Growth Rate was 36.50% per year. The lowest was -394.60% per year. And the median was 5.10% per year.

Enzymatica AB  (STU:EN9) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Enzymatica AB EPS (Basic) Related Terms

Enzymatica AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB EPS (Basic) Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.04 -0.03 -0.02 -0.02

Enzymatica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.00 -0.01 -0.01
STU:EN9
58GF Score
Enzymatica AB STU:EN9
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Enzymatica AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4.768-0)/242.735
=-0.02

Enzymatica AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.249-0)/242.735
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.02 mean?
Enzymatica AB (STU:EN9) has a EPS (Basic) of €-0.02 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Enzymatica AB and its competitors.
Is Enzymatica AB's EPS (Basic) too high?
Enzymatica AB's current EPS (Basic) is €-0.02. Overall, Enzymatica AB has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's EPS (Basic) compare to ZTS?
Enzymatica AB's EPS (Basic) of €-0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current EPS (Basic) is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Enzymatica AB (STU:EN9) has a current EPS (Basic) of €-0.02. The stock's GF Value™ is €0.16, compared to a current price of €0.18 — trading 11.3% above its estimated fair value. The current EPS (Basic) is €-0.02. Enzymatica AB's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Enzymatica AB (STU:EN9), the current EPS (Basic) is €-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (STU:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.18 is trading 11.3% above its estimated GF Value™ of €0.16.

Key valuation signals for STU:EN9:

  • EPS (Basic): €-0.02
  • GF Value™: €0.16 vs. price of €0.18 (11.3% above fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the STU:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:SwedenEN9:Germany
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
58GF Score

Get the complete analysis for STU:EN9

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€0.16
GF Value